Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)

About Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics logoBellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLPH
  • CUSIP: N/A
  • Web: www.bellerophon.com
Capitalization:
  • Market Cap: $44.21 million
  • Outstanding Shares: 32,039,000
Average Prices:
  • 50 Day Moving Avg: $1.41
  • 200 Day Moving Avg: $1.04
  • 52 Week Range: $0.43 - $4.58
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.57 per share
  • Price / Book: 2.42
Profitability:
  • EBIDTA: ($23,710,000.00)
  • Return on Equity: -117.99%
  • Return on Assets: -91.74%
Debt:
  • Current Ratio: 3.67%
  • Quick Ratio: 3.67%
Misc:
  • Average Volume: 1.03 million shs.
  • Beta: -2.64
  • Short Ratio: 2.09
 

Frequently Asked Questions for Bellerophon Therapeutics (NASDAQ:BLPH)

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) released its earnings results on Monday, May, 15th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. View Bellerophon Therapeutics' Earnings History.

Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?

3 brokers have issued 1 year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $4.50 to $5.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $4.75 in the next twelve months. View Analyst Ratings for Bellerophon Therapeutics.

Who are some of Bellerophon Therapeutics' key competitors?

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Who owns Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CVI INVESTMENTS, INC. (5.70%), BOXER CAPITAL, LLC (5.90%), Boxer Capital LLC (5.80%), FMR LLC (3.57%), Renaissance Technologies LLC (1.49%) and Vanguard Group Inc. (1.25%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock. View Institutional Ownership Trends for Bellerophon Therapeutics.

Who sold Bellerophon Therapeutics stock? Who is selling Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Bellerophon Therapeutics.

Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock. View Insider Buying and Selling for Bellerophon Therapeutics.

How do I buy Bellerophon Therapeutics stock?

Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bellerophon Therapeutics stock cost?

One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.38.

Analyst Ratings

Consensus Ratings for Bellerophon Therapeutics (NASDAQ:BLPH) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.75 (244.20% upside)

Analysts' Ratings History for Bellerophon Therapeutics (NASDAQ:BLPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/17/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$4.50HighView Rating Details
2/2/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
8/11/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/22/2016FBR & CoReiterated RatingOutperform$11.00N/AView Rating Details
3/22/2016Leerink SwannLower Price TargetOutperform$11.00 -> $9.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)
Earnings by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Earnings History by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.25)($0.15)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.21)($0.37)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.42)($0.30)ViewN/AView Earnings Details
8/9/2016Q216($0.51)($0.39)ViewN/AView Earnings Details
5/10/2016Q116($0.65)($0.54)ViewN/AView Earnings Details
3/21/2016Q4($1.06)($0.82)ViewListenView Earnings Details
11/12/2015Q315($0.94)($0.86)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.96)($0.90)ViewN/AView Earnings Details
3/31/2015Q4 2014($2.16)($1.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)
2017 EPS Consensus Estimate: ($1.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bellerophon Therapeutics (NASDAQ:BLPH)
Insider Ownership Percentage: 54.20%
Institutional Ownership Percentage: 44.60%
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Institutional Ownership by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Jens LuehringDirectorBuy20,000$0.56$11,200.00View SEC Filing  
5/17/2016Jonathan M PeacockCEOBuy5,000$1.37$6,850.00View SEC Filing  
12/16/2015Jonathan M. PeacockCEOBuy20,300$2.75$55,825.00View SEC Filing  
8/19/2015Jonathan M PeacockCEOBuy5,000$5.48$27,400.00View SEC Filing  
5/20/2015Jonathan M PeacockCEOBuy5,560$8.69$48,316.40View SEC Filing  
2/19/2015Daniel TasseDirectorBuy25,000$12.00$300,000.00View SEC Filing  
2/19/2015Jonathan M PeacockCEOBuy20,800$12.00$249,600.00View SEC Filing  
2/19/2015Linde North America, Inc.Major ShareholderBuy358,916$12.00$4,306,992.00View SEC Filing  
2/19/2015Manesh NaiduInsiderBuy1,500$12.00$18,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bellerophon Therapeutics (NASDAQ:BLPH)
Latest Headlines for Bellerophon Therapeutics (NASDAQ:BLPH)
Source:
DateHeadline
bizjournals.com logoBiotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics
www.bizjournals.com - May 25 at 10:04 PM
prnewswire.com logoBiotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM
streetinsider.com logoBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM
streetinsider.com logoBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse
www.streetinsider.com - May 23 at 11:51 AM
finance.yahoo.com logoPositive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
finance.yahoo.com - May 23 at 11:51 AM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 3:24 PM
globenewswire.com logoBellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 9:41 AM
finance.yahoo.com logoBellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 9:40 AM
finance.yahoo.com logoBellerophon Therapeutics posts 1Q loss
finance.yahoo.com - May 15 at 9:40 AM
reuters.com logoBRIEF-Bellerophon to issue 2 mln registered shares of common stock
www.reuters.com - May 11 at 4:29 PM
streetinsider.com logoBellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, Warrants
www.streetinsider.com - May 11 at 9:15 AM
finance.yahoo.com logoBellerophon Announces $3.0 Million Registered Direct Offering
finance.yahoo.com - May 10 at 8:48 AM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:16 AM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 11:54 PM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Earns Daily News Impact Rating of 0.34
www.americanbankingnews.com - May 2 at 12:52 PM
streetinsider.com logoBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.com
www.streetinsider.com - May 2 at 11:49 AM
streetinsider.com logoBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS
www.streetinsider.com - May 1 at 3:57 PM
finance.yahoo.com logoBellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference
finance.yahoo.com - May 1 at 9:09 AM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:22 AM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Earning Somewhat Critical Media Coverage, Report Shows
www.americanbankingnews.com - April 24 at 6:08 PM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 12:33 PM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) Short Interest Down 0.6% in March
www.americanbankingnews.com - April 20 at 7:54 PM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Given Daily Coverage Optimism Rating of 0.10
www.americanbankingnews.com - April 17 at 2:08 PM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) Receives New Coverage from Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - April 17 at 9:51 AM
americanbankingnews.com logoBellerophon Therapeutics (BLPH) Receiving Somewhat Negative Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 7:58 AM
finance.yahoo.com logoBellerophon Slumps on Underwhelming INOpulse Data
finance.yahoo.com - April 7 at 3:53 PM
streetinsider.com logoBellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulse® for Pulmonary Arterial Hypertension at ... - StreetInsider.com
www.streetinsider.com - April 7 at 8:34 AM
americanbankingnews.com logoShort Interest in Bellerophon Therapeutics Inc (BLPH) Grows By 43.6%
www.americanbankingnews.com - March 28 at 8:23 AM
finance.yahoo.com logoBellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
finance.yahoo.com - March 27 at 11:40 AM
finance.yahoo.com logoThe Difference Between Spectacular News and No News
finance.yahoo.com - March 21 at 4:18 PM
biz.yahoo.com logoBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
biz.yahoo.com - March 16 at 3:17 PM
finance.yahoo.com logoBELLEROPHON THERAPEUTICS, INC. Financials
finance.yahoo.com - March 16 at 3:17 PM
americanbankingnews.com logoBellerophon Therapeutics Inc (BLPH) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 14 at 9:58 AM
nasdaq.com logoAPRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX
www.nasdaq.com - March 14 at 8:42 AM
biz.yahoo.com logoBELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 13 at 11:49 AM
us.rd.yahoo.com logoBellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 13 at 11:49 AM
biz.yahoo.com logoBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 13 at 11:49 AM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Bellerophon Therapeutics
finance.yahoo.com - February 23 at 3:55 PM
benzinga.com logo18 Biggest Mid-Day Gainers For Tuesday - Benzinga
www.benzinga.com - February 21 at 3:16 PM
finance.yahoo.com logoCoverage initiated on Bellerophon Therapeutics by H.C. Wainwright
finance.yahoo.com - January 20 at 5:01 PM

Social

Chart

Bellerophon Therapeutics (BLPH) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff